Skip to main content
Signal8

Benitec Biopharma Inc. (BNTC)

Benitec Biopharma Inc., a clinical-stage biotechnology company, focuses on the development of novel genetic medicines. Its Silence and Replace, a DNA-directedRNA interference platform combines RNA interference with gene therapy to create medicines that simultaneously facilitate sustained silencing of disease-causing genes and concomitant delivery of wildtype replacement genes following a single administration of the therapeutic construct. The company is developing BB-301, an AAV-based gene therapy designed to silence the expression of the disease-causing gene for the treatment of oculopharyngeal muscular dystrophy related dysphagia. Benitec Biopharma Inc. is headquartered in Hayward, California.

Sector: Pharmaceutical Preparations

Industry: Biotechnology

Benitec Biopharma Inc. logo

Benitec Biopharma Inc.

NASDAQ:BNTCHealthcare
+10.42%$9.54
AH$9.54+0.00%vs close
Mkt Cap$332.84M
Float23.26M
O/S34.89M
Inst Own94.8%
SI8.6%
Dilution
Benitec Biopharma Inc. logoNASDAQ:BNTC$9.54+10.42%
FormDescription
8-K
7.01,9.01
3
DEFA14A
Additional Proxy Materials
DEF 14A
Definitive Proxy Statement
4
8-K
7.01,9.01
3
8-K
4.01
8-K
4.01,9.01
2
EFFECT
Notice of Effectiveness
1
S-3
Shelf Registration Statement
3
10-K
Annual Report
6
8-K
2.02,9.01
3
4
Statement of Changes in Beneficial Ownership
8-K
5.02
4
Statement of Changes in Beneficial Ownership
3
Initial Statement of Beneficial Ownership
10-Q
Quarterly Report
8-K
2.02,9.01
UPLOAD
SEC Filing
CORRESP
SEC Filing
1
10-K/A
Annual Report (Amended)
UPLOAD
SEC Filing
2
8-K
2.02,9.01
10-Q
Quarterly Report
424B3
Prospectus
EFFECT
Notice of Effectiveness
CORRESP
SEC Filing

1-25 of 334

…

Recent SEC filings with analysis